Piper Sandler analyst Matt O’Brien double downgraded Humacyte to Underweight from Overweight with a price target of $4, down from $10, post the Q1 results. With the sizable share pullback in several commercial stage companies, there are better alternatives compared to a pre-revenue company like Humacyte “in this volatile tape,” O’Brien tells investors in a research note. The analyst recognizes the “strong technology” Humacyte has developed and sees a future for the company given its multiple ongoing clinical programs in large markets. However, he believes the stock “will struggle in the near term.”
previous post